Robert J Lewandowski

List of Publications by Year
in descending order

236	14,505	18465 62	21521 114
papers	citations	h-index	g-index

238	238	238	7055
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes. Gastroenterology, 2010, 138, 52-64.	0.6	925
2	Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology, 2011, 140, 497-507.e2.	0.6	566
3	Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology, 2008, 47, 71-81.	3.6	542
4	Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients WithÂHepatocellular Carcinoma. Gastroenterology, 2016, 151, 1155-1163.e2.	0.6	498
5	Treatment of Unresectable Hepatocellular Carcinoma with Use of 90Y Microspheres (TheraSphere): Safety, Tumor Response, and Survival. Journal of Vascular and Interventional Radiology, 2005, 16, 1627-1639.	0.2	392
6	Yttrium-90 microspheres (TheraSphereÂ®) treatment of unresectable hepatocellular carcinoma: Downstaging to resection, RFA and bridge to transplantation. Journal of Surgical Oncology, 2006, 94, 572-586.	0.8	297
7	Angiographic Considerations in Patients Undergoing Liver-directed Therapy. Journal of Vascular and Interventional Radiology, 2005, 16, 911-935.	0.2	237
8	Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: Multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology, 2014, 60, 192-201.	3.6	237
9	Radioembolization with 90Y Microspheres: Angiographic and Technical Considerations. CardioVascular and Interventional Radiology, 2007, 30, 571-592.	0.9	232
10	Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology, 2009, 49, 1185-1193.	3.6	229
11	Increased Quality of Life Among Hepatocellular Carcinoma Patients Treated With Radioembolization, Compared With Chemoembolization. Clinical Gastroenterology and Hepatology, 2013, 11, 1358-1365.e1.	2.4	220
12	Radiation lobectomy: Time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. Journal of Hepatology, 2013, 59, 1029-1036.	1.8	215
13	Yttriumâ€90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology, 2021, 74, 2342-2352.	3.6	215
14	90Y Radioembolization for Metastatic Neuroendocrine Liver Tumors. Annals of Surgery, 2008, 247, 1029-1035.	2.1	213
15	Treatment of Unresectable Primary and Metastatic Liver Cancer with Yttrium-90 Microspheres (TheraSphereÂ®): Assessment of Hepatic Arterial Embolization. CardioVascular and Interventional Radiology, 2006, 29, 522-529.	0.9	210
16	Unresectable Chemorefractory Liver Metastases: Radioembolization with⁹⁰Y Microspheresâ€"Safety, Efficacy, and Survival. Radiology, 2008, 247, 507-515.	3.6	207
17	Radiation Lobectomy: Preliminary Findings of Hepatic Volumetric Response to Lobar Yttrium-90 Radioembolization. Annals of Surgical Oncology, 2009, 16, 1587-1596.	0.7	207
18	Transcatheter Intraarterial Therapies: Rationale and Overview. Radiology, 2011, 259, 641-657.	3.6	206

#	Article	IF	Citations
19	Use of Yttrium-90 Glass Microspheres (TheraSphere) for the Treatment of Unresectable Hepatocellular Carcinoma in Patients with Portal Vein Thrombosis. Journal of Vascular and Interventional Radiology, 2004, 15, 335-345.	0.2	201
20	Alpha-Fetoprotein Response After Locoregional Therapy for Hepatocellular Carcinoma: Oncologic Marker of Radiologic Response, Progression, and Survival. Journal of Clinical Oncology, 2009, 27, 5734-5742.	0.8	199
21	Radiation Segmentectomy: A Novel Approach to Increase Safety and Efficacy of Radioembolization. International Journal of Radiation Oncology Biology Physics, 2011, 79, 163-171.	0.4	199
22	Yttrium-90 Radioembolization for Intrahepatic Cholangiocarcinoma: Safety, Response, and Survival Analysis. Journal of Vascular and Interventional Radiology, 2013, 24, 1227-1234.	0.2	194
23	Research Reporting Standards for Radioembolization of Hepatic Malignancies. Journal of Vascular and Interventional Radiology, 2011, 22, 265-278.	0.2	185
24	Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000â€patient 15â€year experience. Hepatology, 2018, 68, 1429-1440.	3.6	174
25	Improving Inferior Vena Cava Filter Retrieval Rates: Impact of a Dedicated Inferior Vena Cava Filter Clinic. Journal of Vascular and Interventional Radiology, 2010, 21, 1847-1851.	0.2	172
26	Imaging Response in the Primary Index Lesion and Clinical Outcomes Following Transarterial Locoregional Therapy for Hepatocellular Carcinoma. JAMA - Journal of the American Medical Association, 2010, 303, 1062.	3.8	170
27	Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma. Radiology, 2018, 287, 1050-1058.	3.6	168
28	Radioembolization of colorectal hepatic metastases using yttriumâ€90 microspheres. Cancer, 2009, 115, 1849-1858.	2.0	164
29	90Y Microsphere (TheraSphere) Treatment for Unresectable Colorectal Cancer Metastases of the Liver: Response to Treatment at Targeted Doses of 135â€“150 Gy as Measured by [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomographic Imaging. Journal of Vascular and Interventional Radiology, 2005, 16, 1641-1651.	0.2	162
30	Incidence of Radiation Pneumonitis After Hepatic Intra-Arterial Radiotherapy With Yttrium-90 Microspheres Assuming Uniform Lung Distribution. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 431-438.	0.6	157
31	Comparison of Complication Rates Associated with Permanent and Retrievable Inferior Vena Cava Filters: A Review of the MAUDE Database. Journal of Vascular and Interventional Radiology, 2014, 25, 1181-1185.	0.2	151
32	Radiographic Response to Locoregional Therapy in Hepatocellular Carcinoma Predicts Patient Survival Times. Gastroenterology, 2011, 141, 526-535.e2.	0.6	148
33	Chemoembolization for Hepatocellular Carcinoma: Comprehensive Imaging and Survival Analysis in a 172-Patient Cohort. Radiology, 2010, 255, 955-965.	3.6	141
34	Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: Radiologicâ€“pathologic correlation. Journal of Hepatology, 2011, 54, 695-704.	1.8	140
35	Radioembolization for Neuroendocrine Liver Metastases: Safety, Imaging, and Long-Term Outcomes. International Journal of Radiation Oncology Biology Physics, 2012, 83, 887-894.	0.4	137
36	Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. Journal of Hepatology, 2017, 66, 1173-1181.	1.8	135

#	Article	IF	Citations
37	Multimodality Imaging Following⁹⁰Y Radioembolization: A Comprehensive Review and Pictorial Essay. Radiographics, 2008, 28, 81-99.	1.4	128
38	Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma. Advances in Therapy, 2016, 33, 699-714.	1.3	123
39	Technical Aspects of Radioembolization with 90Y Microspheres. Techniques in Vascular and Interventional Radiology, 2007, 10, 12-29.	0.4	121
40	Radioembolization for hepatocellular carcinoma with portal vein thrombosis: Impact of liver function on systemic treatment options at disease progression. Journal of Hepatology, 2013, 58, 73-80.	1.8	110
41	Radiation Dose Limits and Liver Toxicities Resulting from Multiple Yttrium-90 Radioembolization Treatments for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2007, 18, 1375-1382.	0.2	107
42	Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions. Journal of Vascular and Interventional Radiology, 2017, 28, 1-15.	0.2	107
43	Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy. Journal of Vascular and Interventional Radiology, 2017, 28, 1210-1223.e3.	0.2	103
44	Pretransplantation Portal Vein Recanalization and Transjugular Intrahepatic Portosystemic Shunt Creation for Chronic Portal Vein Thrombosis: Final Analysis of a 61-Patient Cohort. Journal of Vascular and Interventional Radiology, 2017, 28, 1714-1721.e2.	0.2	101
45	Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria. Journal of Vascular and Interventional Radiology, 2016, 27, 457-473.	0.2	98
46	90Y Radioembolization of Metastatic Breast Cancer to the Liver: Toxicity, Imaging Response, Survival. Journal of Vascular and Interventional Radiology, 2007, 18, 621-628.	0.2	92
47	⁹⁰Y radiation lobectomy: Outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. Journal of Surgical Oncology, 2016, 114, 99-105.	0.8	89
48	Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdominal Imaging, 2009, 34, 566-581.	2.0	88
49	Effect of C-arm Angiographic CT on Transcatheter Arterial Chemoembolization of Liver Tumors. Journal of Vascular and Interventional Radiology, 2007, 18, 1305-1309.	0.2	87
50	Comparison of Hypoxia-inducible Factor-1Î± Expression before and after Transcatheter Arterial Embolization in Rabbit VX2 Liver Tumors. Journal of Vascular and Interventional Radiology, 2008, 19, 1483-1489.	0.2	83
51	Chemoembolization and Radioembolization for Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2013, 11, 604-611.	2.4	83
52	Yttrium-90 Radioembolization of Hepatocellular Carcinoma and Metastatic Disease to the Liver. Seminars in Interventional Radiology, 2006, 23, 064-072.	0.3	82
53	Radiologicâ€“Pathologic Correlation of Hepatocellular Carcinoma Treated with Chemoembolization. CardioVascular and Interventional Radiology, 2010, 33, 1143-1152.	0.9	82
54	Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: A subgroup analysis. Journal of Hepatology, 2012, 56, 1112-1120.	1.8	82

#	Article	IF	Citations
55	Prospective randomized pilot study of Y90+/â^'sorafenib as bridge to transplantation in hepatocellular carcinoma. Journal of Hepatology, 2014, 61, 309-317.	1.8	80
56	Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1861-1869.	3.3	80
57	⁹⁰Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study. Journal of Nuclear Medicine, 2016, 57, 665-671.	2.8	79
58	Radioembolization for Primary and Metastatic Liver Cancer. Seminars in Radiation Oncology, 2011, 21, 294-302.	1.0	78
59	Portal Vein Recanalization and Transjugular Intrahepatic Portosystemic Shunt Creation for Chronic Portal Vein Thrombosis: Technical Considerations. Techniques in Vascular and Interventional Radiology, 2016, 19, 52-60.	0.4	78
60	Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 580-583.	3.3	78
61	Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 Â± sorafenib. Hepatology, 2013, 58, 1655-1666.	3.6	66
62	Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2018, 29, 1502-1510.e1.	0.2	65
63	Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2016, 27, 795-802.	0.2	64
64	The Effect of Catheter-Directed CT Angiography on Yttrium-90 Radioembolization Treatment of Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2005, 16, 1085-1091.	0.2	63
65	A Comparison of Chemoembolization Endpoints Using Angiographic versus Transcatheter Intraarterial Perfusion/MR Imaging Monitoring. Journal of Vascular and Interventional Radiology, 2007, 18, 1249-1257.	0.2	62
66	Liver Transplantation Following Yttriumâ€90 Radioembolization: 15â€Year Experience in 207â€Patient Cohort. Hepatology, 2021, 73, 998-1010.	3.6	62
67	Chemoembolization Endpoints: Effect on Survival Among Patients With Hepatocellular Carcinoma. American Journal of Roentgenology, 2011, 196, 919-928.	1.0	61
68	Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). Cancers, 2019, 11, 1085.	1.7	60
69	Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial. Journal of Clinical Oncology, 2021, 39, 3897-3907.	0.8	59
70	Long-Term Hepatotoxicity of Yttrium-90 Radioembolization as Treatment of Metastatic Neuroendocrine Tumor toÂtheÂLiver. Journal of Vascular and Interventional Radiology, 2017, 28, 1520-1526.	0.2	57
71	The Role of Tumor Vascularity in Predicting Survival after Yttrium-90 Radioembolization for Liver Metastases. Journal of Vascular and Interventional Radiology, 2009, 20, 1564-1569.	0.2	56
72	Poly(lactide-co-glycolide) microspheres for MRI-monitored transcatheter delivery of sorafenib to liver tumors. Journal of Controlled Release, 2014, 184, 10-17.	4.8	56

#	Article	IF	Citations
73	Retrievable IVC Filters: Comprehensive Review of Device-related Complications and Advanced Retrieval Techniques. Radiographics, 2017, 37, 1236-1245.	1.4	56
74	Yttrium-90 Radioembolization Stops Progression of Targeted Breast Cancer Liver Metastases after Failed Chemotherapy. Journal of Vascular and Interventional Radiology, 2014, 25, 1523-1532.e2.	0.2	55
75	Comparison of Two Different Methods for Inoculating VX2 Tumors in Rabbit Livers and Hind Limbs. Journal of Vascular and Interventional Radiology, 2008, 19, 931-936.	0.2	54
76	⁹⁰Y Radioembolization for Locally Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Long-Term Outcomes in a 185-Patient Cohort. Journal of Nuclear Medicine, 2018, 59, 1042-1048.	2.8	54
77	Outpatient Single-Session Yttrium-90 Glass Microsphere Radioembolization. Journal of Vascular and Interventional Radiology, 2014, 25, 266-270.	0.2	53
78	Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma. Hepatology, 2015, 62, 1111-1121.	3.6	51
79	Same-day 90Y radioembolization: implementing a new treatment paradigm. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2353-2359.	3.3	51
80	Transcatheter Intraarterial Perfusion: MR Monitoring of Chemoembolization for Hepatocellular Carcinomaâ€"Feasibility of Initial Clinical Translation. Radiology, 2008, 246, 964-971.	3.6	48
81	Diffusion-weighted magnetic resonance imaging to predict response of hepatocellular carcinoma to chemoembolization. World Journal of Gastroenterology, 2010, 16, 3161.	1.4	44
82	Poly(lactide-co-glycolide) microspheres for MRI-monitored delivery of sorafenib in a rabbit VX2 model. Biomaterials, 2015, 61, 299-306.	5.7	44
83	Chemoradiation of Hepatic Malignancies: Prospective, Phase 1 Study of Full-Dose Capecitabine With Escalating Doses of Yttrium-90 Radioembolization. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1025-1031.	0.4	43
84	Prognostic Role of Albumin, Bilirubin, and ALBI Scores: Analysis of 1000 Patients with Hepatocellular Carcinoma Undergoing Radioembolization. Cancers, 2019, 11, 879.	1.7	43
85	Yttrium-90 Radioembolization for Liver Malignancies: Prognostic Factors Associated with Survival. Journal of Vascular and Interventional Radiology, 2010, 21, 90-95.	0.2	42
86	Percutaneous Cryoablation for the Treatment of Primary and Metastatic Lung Tumors: Identification of Risk Factors for Recurrence and Major Complications. Journal of Vascular and Interventional Radiology, 2016, 27, 1371-1379.	0.2	41
87	Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses. Hepatology, 2018, 67, 873-883.	3.6	41
88	Noncirrhotic complete obliterative portal vein thrombosis: Novel management using transâ€splenic transjugular intrahepatic portosystemic shunt with portal vein recanalization. Hepatology, 2016, 63, 1387-1390.	3.6	40
89	Prophylactic Embolization of the Gastroduodenal and Right Gastric Arteries Is Not Routinely Necessary before Radioembolization with Glass Microspheres. Journal of Vascular and Interventional Radiology, 2013, 24, 1743-1745.	0.2	39
90	Comparison of the Adverse Event Profile of TheraSphereÂ® with SIR-SpheresÂ® for the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review. CardioVascular and Interventional Radiology, 2017, 40, 1033-1043.	0.9	39

#	Article	IF	Citations
91	Defining Prolonged Dwell Time: When Are Advanced Inferior Vena Cava Filter Retrieval Techniques Necessary?. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	39
92	Advances in Degradable Embolic Microspheres: A State of the Art Review. Journal of Functional Biomaterials, 2018, 9, 14.	1.8	39
93	Agreement between Competing Imaging Measures of Response of Hepatocellular Carcinoma to Yttrium-90 Radioembolization. Journal of Vascular and Interventional Radiology, 2010, 21, 515-521.	0.2	38
94	The Role of Percutaneous Image-Guided Thermal Ablation for the Treatment of Pulmonary Malignancies. American Journal of Roentgenology, 2017, 209, 740-751.	1.0	38
95	Transarterial approaches to primary and secondary hepatic malignancies. Nature Reviews Clinical Oncology, 2015, 12, 481-489.	12.5	37
96	Retrieval of Inferior Vena Cava Filters With Prolonged Dwell Time. JAMA Internal Medicine, 2015, 175, 1572.	2.6	36
97	Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional OncologyÂProcedures. Journal of Vascular and Interventional Radiology, 2017, 28, 1487-1494.	0.2	33
98	Evolution of Radioembolization in Treatment of Hepatocellular Carcinoma: A Pictorial Review. Radiographics, 2021, 41, 1802-1818.	1.4	33
99	Streamlining radioembolization in UNOS T1/T2 hepatocellular carcinoma by eliminating lung shunt estimation. Journal of Hepatology, 2020, 72, 1151-1158.	1.8	32
100	TIPS for Adults Without Cirrhosis With Chronic Mesenteric Venous Thrombosis and EHPVO Refractory to Standardâ€ofâ€Care Therapy. Hepatology, 2021, 74, 2735-2744.	3.6	32
101	Recent progress in cryoablation cancer therapy and nanoparticles mediated cryoablation. Theranostics, 2022, 12, 2175-2204.	4.6	32
102	Optimization of Radioembolic Effect with Extended-shelf-life Yttrium-90 Microspheres: Results from a Pilot Study. Journal of Vascular and Interventional Radiology, 2009, 20, 1557-1563.	0.2	31
103	Treating and Downstaging Hepatocellular Carcinoma in the Caudate Lobe with Yttrium-90 Radioembolization. CardioVascular and Interventional Radiology, 2012, 35, 1094-1101.	0.9	30
104	Hepatic imaging following intra-arterial embolotherapy. Abdominal Radiology, 2016, 41, 600-616.	1.0	30
105	Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization. European Journal of Radiology, 2017, 93, 100-106.	1.2	30
106	Imaging tumor response following liver-directed intra-arterial therapy. Abdominal Imaging, 2013, 38, 1286-1299.	2.0	28
107	Locoregional Therapy of Hepatocellular Carcinoma. Clinics in Liver Disease, 2015, 19, 401-420.	1.0	28
108	Pickering-Emulsion for Liver Trans-Arterial Chemo-Embolization with Oxaliplatin. CardioVascular and Interventional Radiology, 2018, 41, 781-788.	0.9	28

#	Article	IF	Citations
109	Neoadjuvant Radiation Lobectomy As an Alternative to Portal Vein Embolization in Hepatocellular Carcinoma. Seminars in Nuclear Medicine, 2019, 49, 197-203.	2.5	28
110	Analysis of the RENAL and mRENAL Scores and the Relative Importance of Their Components in the Prediction of Complications and Local Progression after Percutaneous Renal Cryoablation. Journal of Vascular and Interventional Radiology, 2017, 28, 860-867.	0.2	27
111	TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial. JMIR Research Protocols, 2019, 8, e11545.	0.5	27
112	Cancer Concepts and Principles: Primer for the Interventional Oncologistâ€”Part II. Journal of Vascular and Interventional Radiology, 2013, 24, 1167-1188.	0.2	26
113	Pictorial essay: imaging findings following Y90 radiation segmentectomy for hepatocellular carcinoma. Abdominal Radiology, 2018, 43, 1723-1738.	1.0	25
114	Comparing Real World, Personalized, Multidisciplinary Tumor Board Recommendations with BCLC Algorithm: 321-Patient Analysis. CardioVascular and Interventional Radiology, 2021, 44, 1070-1080.	0.9	25
115	Four-dimensional Transcatheter Intraarterial Perfusion MR Imaging for Monitoring Chemoembolization of Hepatocellular Carcinoma: Preliminary Results. Journal of Vascular and Interventional Radiology, 2008, 19, 1589-1595.	0.2	24
116	Quantitative 4D transcatheter intraarterial perfusion MRI for monitoring chemoembolization of hepatocellular carcinoma. Journal of Magnetic Resonance Imaging, 2010, 31, 1106-1116.	1.9	22
117	Yttrium-90 Radioembolization for the Treatment of Unresectable Hepatocellular Carcinoma in Patients with Transjugular Intrahepatic Portosystemic Shunts. Journal of Vascular and Interventional Radiology, 2013, 24, 74-80.	0.2	21
118	Sustained safety and efficacy of extended-shelf-life 90Y glass microspheres: long-term follow-up in a 134-patient cohort. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 486-493.	3.3	21
119	Intraarterial Hepatic SPECT/CT Imaging Using 99mTc-Macroaggregated Albumin in Preparation for Radioembolization. Journal of Nuclear Medicine, 2015, 56, 1157-1162.	2.8	21
120	On-demand degradable embolic microspheres for immediate restoration of blood flow during image-guided embolization procedures. Biomaterials, 2021, 265, 120408.	5.7	21
121	Comparative Study of Staging Systems for Hepatocellular Carcinoma in 428 Patients Treated with Radioembolization. Journal of Vascular and Interventional Radiology, 2014, 25, 1056-1066.	0.2	20
122	Can volumetric ADC measurement help predict response to Y90 radioembolization in HCC?. Abdominal Imaging, 2015, 40, 1471-1480.	2.0	20
123	A Comparison of Retrievability: Celect versus Option Filter. Journal of Vascular and Interventional Radiology, 2015, 26, 865-869.	0.2	20
124	Radioembolization as a Treatment Strategy for Metastatic Colorectal Cancer to the Liver: What Can We Learn from the SIRFLOX Trial?. Current Treatment Options in Oncology, 2016, 17, 26.	1.3	20
125	Angiogenic Response following Radioembolization: Results from a Randomized Pilot Study of Yttrium-90 with or without Sorafenib. Journal of Vascular and Interventional Radiology, 2016, 27, 1329-1336.	0.2	20
126	Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2018, 41, 1557-1565.	0.9	20

#	Article	IF	Citations
127	Adverse Events Related to Partial Splenic Embolization for the Treatment of Hypersplenism: A Systematic Review. Journal of Vascular and Interventional Radiology, 2020, 31, 1118-1131.e6.	0.2	20
128	Prospective Evaluation of Patients with Early-/Intermediate-stage Hepatocellular Carcinoma with Disease Progression Following Arterial Locoregional Therapy: Candidacy for Systemic Treatment or Clinical Trials. Journal of Vascular and Interventional Radiology, 2013, 24, 1189-1197.e2.	0.2	18
129	Localized Hyperthermia with Iron Oxideâ€“Doped Yttrium Microparticles: Steps toward Image-Guided Thermoradiotherapy in Liver Cancer. Journal of Vascular and Interventional Radiology, 2014, 25, 397-404.	0.2	18
130	Multicenter Trial of the VenaTech Convertible Vena Cava Filter. Journal of Vascular and Interventional Radiology, 2017, 28, 1353-1362.	0.2	18
131	Intraprocedural Transcatheter Intra-arterial Perfusion MRI as a Predictor of Tumor Response to Chemoembolization for Hepatocellular Carcinoma. Academic Radiology, 2011, 18, 828-836.	1.3	17
132	Fibrin Cap Disruption: An Adjunctive Technique for Inferior Vena Cava Filter Retrieval. Journal of Vascular and Interventional Radiology, 2012, 23, 1233-1235.	0.2	17
133	Perfusion Reduction at Transcatheter Intraarterial Perfusion MR Imaging: A Promising Intraprocedural Biomarker to Predict Transplant-Free Survival during Chemoembolization of Hepatocellular Carcinoma. Radiology, 2014, 272, 587-597.	3.6	17
134	Assessing Imaging Response to Therapy. Radiologic Clinics of North America, 2015, 53, 1077-1088.	0.9	17
135	Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2195-2202.	3.3	17
136	Survival Analysis of Advanced HCC Treated with Radioembolization: Comparing Impact of Clinical Performance Status Versus Vascular Invasion/Metastases. CardioVascular and Interventional Radiology, 2018, 41, 260-269.	0.9	17
137	Percutaneous management of malignant biliary disease. Journal of Surgical Oncology, 2019, 120, 45-56.	0.8	17
138	Modified Radiation Lobectomy: An Evolving Paradigm to Convert Patients to Liver Resection Candidacy. Seminars in Interventional Radiology, 2019, 36, 343-348.	0.3	17
139	Comparison of Transcatheter Intraarterial Perfusion MR Imaging and Fluorescent Microsphere Perfusion Measurements during Transcatheter Arterial Embolization of Rabbit Liver Tumors. Journal of Vascular and Interventional Radiology, 2007, 18, 1280-1286.	0.2	16
140	Development and Validation of Sorafenib-eluting Microspheres to Enhance Therapeutic Efficacy of Transcatheter Arterial Chemoembolization in a Rat Model of Hepatocellular Carcinoma. Radiology Imaging Cancer, 2021, 3, e200006.	0.7	16
141	Quantitative 4D Transcatheter Intraarterial Perfusion MRI for Standardizing Angiographic Chemoembolization Endpoints. American Journal of Roentgenology, 2011, 197, 1237-1243.	1.0	15
142	Interventional radiology in the management of the liver transplant patient. Liver Transplantation, 2017, 23, 1328-1341.	1.3	15
143	Contemporary Systematic Review of Health-Related Quality of Life Outcomes in Locoregional Therapies for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2019, 30, 1924-1933.e2.	0.2	15
144	Single-session inferior vena cava filter removal, recanalization, and endovenous reconstruction for chronic iliocaval thrombosis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2019, 7, 176-183.	0.9	15

#	Article	IF	Citations
145	Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival. Journal of Vascular and Interventional Radiology, 2016, 27, 1279-1287.	0.2	14
146	Retrieval of Inferior Vena Cava Filters: Technical Considerations. Seminars in Interventional Radiology, 2016, 33, 144-148.	0.3	14
147	Yttrium-90 Radioembolization for Breast Cancer Liver Metastases. Journal of Vascular and Interventional Radiology, 2016, 27, 1316-1319.	0.2	14
148	Yttrium-90 Radioembolization for Hepatocellular Carcinoma. Seminars in Nuclear Medicine, 2016, 46, 105-108.	2.5	14
149	JOURNAL CLUB: Four-Dimensional Flow MRIâ€"Based Splenic Flow Index for Predicting Cirrhosis-Associated Hypersplenism. American Journal of Roentgenology, 2017, 209, 46-54.	1.0	14
150	Surveillance, anticoagulation, or filter in calf vein thrombosis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2017, 5, 25-32.	0.9	14
151	Vena Cava Filter Retrieval with Aorto-Iliac Arterial Strut Penetration. CardioVascular and Interventional Radiology, 2018, 41, 1184-1188.	0.9	14
152	MRI-Monitored Intra-Tumoral Injection of Iron-Oxide Labeled Clostridium novyi-NT Anaerobes in Pancreatic Carcinoma Mouse Model. PLoS ONE, 2014, 9, e116204.	1.1	14
153	Technical Aspects and Practical Approach Toward Same-Day Y90 Radioembolization in the Management of Hepatocellular Carcinoma. Techniques in Vascular and Interventional Radiology, 2019, 22, 93-99.	0.4	13
154	MR imaging findings of the prostate gland following prostate artery embolization: results from a prospective phase 2 study. Abdominal Radiology, 2019, 44, 713-722.	1.0	13
155	SPIO-labeled Yttrium Microspheres for MR Imaging Quantification of Transcatheter Intrahepatic Delivery in a Rodent Model. Radiology, 2016, 278, 405-412.	3.6	12
156	Response and Overall Survival for Yttrium-90 Radioembolization of Hepatic Sarcoma: A Multicenter Retrospective Study. Journal of Vascular and Interventional Radiology, 2018, 29, 867-873.	0.2	12
157	Is hepatectomy safe following Yttrium-90 therapy? A multi-institutional international experience. Hpb, 2019, 21, 1520-1526.	0.1	12
158	Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 807-815.	3.3	12
159	Making the Case: Intra-arterial Therapy for Less Common Metastases. Seminars in Interventional Radiology, 2017, 34, 132-139.	0.3	12
160	Yttrium-90 Radioembolization is a Viable Treatment Option for Unresectable, Chemorefractory Colorectal Cancer Liver Metastases: Further Evidence in Support of a New Treatment Paradigm. Annals of Surgical Oncology, 2015, 22, 706-707.	0.7	11
161	Gastric injury from 90Y to left hepatic lobe tumors adjacent to the stomach: fact or fiction?. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 2038-2044.	3.3	11
162	Clinical and Imaging Follow-up Practices after Transarterial Therapy for Primary and Secondary Hepatic Malignancies. Academic Radiology, 2015, 22, 1510-1515.	1.3	11

#	Article	IF	Citations
163	Percutaneous Access of the Modified Hutson Loop for Retrograde Cholangiography, Endoscopy, and Biliary Interventions. Journal of Vascular and Interventional Radiology, 2020, 31, 2113-2120.e1.	0.2	11
164	Yttrium-90 Radioembolization to the Prostate Gland: Proof of Concept in a Canine Model andÂClinical Translation. Journal of Vascular and Interventional Radiology, 2021, 32, 1103-1112.e12.	0.2	11
165	MR Imaging Perfusion Mismatch: A Technique to Verify Successful Targeting of Liver Tumors during Transcatheter Arterial Chemoembolization. Journal of Vascular and Interventional Radiology, 2008, 19, 698-705.	0.2	10
166	Transarterial Chemoembolization and Yittrium-90 for Liver Cancer and Other Lesions. Clinics in Liver Disease, 2014, 18, 877-890.	1.0	10
167	Indicators of Lung Shunt Fraction Determined by Technetium-99Âm Macroaggregated Albumin in Patients with Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2017, 40, 1213-1222.	0.9	10
168	Locoregional Therapies for the Treatment of Hepatic Metastases from Breast and Gynecologic Cancers. Seminars in Interventional Radiology, 2018, 35, 029-034.	0.3	10
169	Pretransplant Intra-arterial Liver-Directed Therapy Does Not Increase the Risk of Hepatic Arterial Complications in Liver Transplantation: A Single-Center 10-Year Experience. CardioVascular and Interventional Radiology, 2018, 41, 231-238.	0.9	10
170	Yttrium-90 Radioembolization of Unresectable Intrahepatic Cholangiocarcinoma: Long-Term Follow-up for a 136-Patient Cohort. CardioVascular and Interventional Radiology, 2022, 45, 1117-1128.	0.9	10
171	Intra-Arterial Therapies for Liver Masses. Radiologic Clinics of North America, 2015, 53, 973-984.	0.9	9
172	Quality of Life after Radioembolization for Hepatocellular Carcinoma Using a Digital Patient-Reported Outcome Tool. Journal of Vascular and Interventional Radiology, 2020, 31, 311-314.e1.	0.2	9
173	Inferior Vena Cava Filter Retrieval: Patient Selection, Procedural Planning, and Postprocedural Complications. American Journal of Roentgenology, 2020, 215, 790-794.	1.0	9
174	¹⁸F-FDG PET Biomarkers Help Detect Early Metabolic Response to Irreversible Electroporation and Predict Therapeutic Outcomes in a Rat Liver Tumor Model. Radiology, 2018, 287, 137-145.	3.6	8
175	Radioembolization in Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology, 2018, 36, 1898-1901.	0.8	8
176	A phase I study of nivolumab (NIVO) in combination with TheraSphere (Yttrium-90) in patients with advanced hepatocellular cancer.. Journal of Clinical Oncology, 2021, 39, e16183-e16183.	0.8	8
177	Inferior Vena Cava Thrombosis Risk in 1582 Patients with Inferior Vena Cava Filters. Radiology, 2022, 303, 300-302.	3.6	8
178	Locoregional Chemoembolic Delivery: Prediction With Transcatheter Intraarterial Perfusion MRI. American Journal of Roentgenology, 2012, 198, 1196-1202.	1.0	7
179	Yttrium-90 Radioembolization of Hepatocellular Carcinomaâ€“Performance, Technical Advances, and Future Concepts. Seminars in Interventional Radiology, 2015, 32, 388-397.	0.3	7
180	The Utility of Unilobar Technetium-99m Macroaggregated Albumin to Predict Pulmonary Toxicity In Bilobar Hepatocellular Carcinoma prior to Yttrium-90 Radioembolization. Journal of Vascular and Interventional Radiology, 2016, 27, 1453-1456.	0.2	7

#	Article	IF	Citations
181	Microwave or radiofrequency ablation: clinically equivalent?. The Lancet Gastroenterology and Hepatology, 2018, 3, 291-292.	3.7	6
182	The Management of Colorectal Cancer Liver Metastases: The Interventional Radiology Viewpoint. International Journal of Radiation Oncology Biology Physics, 2019, 103, 537-539.	0.4	6
183	Toxicity and Survival of Hepatocellular Carcinoma Patients with Hepatitis B Infection Treated with Yttrium-90 Radioembolization: An Updated 15-Year Study. Journal of Vascular and Interventional Radiology, 2020, 31, 401-408.e1.	0.2	6
184	Yttrium-90 Radioembolization and Tumor Hypoxia: Gas-challenge BOLD Imaging in the VX2 Rabbit Model of Hepatocellular Carcinoma. Academic Radiology, 2020, 28, 849-858.	1.3	6
185	Safety and Efficacy of Segmental Yttrium-90 Radioembolization for Hepatocellular Carcinoma after Transjugular Intrahepatic Portosystemic Shunt Creation. Journal of Vascular and Interventional Radiology, 2021, 32, 211-219.	0.2	6
186	Complications of Percutaneous Biliary Procedures. Seminars in Interventional Radiology, 2021, 38, 364-372.	0.3	6
187	Embolic Agents: Coils. Seminars in Interventional Radiology, 2022, 39, 113-118.	0.3	6
188	Yttrium-90 for colorectal liver metastasis - the promising role of radiation segmentectomy as an alternative local cure. International Journal of Hyperthermia, 2022, 39, 620-626.	1.1	6
189	Response by Desai et al to Letter Regarding Article, â€œDefining Prolonged Dwell Time: When Are Advanced Inferior Vena Cava Filter Retrieval Techniques Necessary? An Analysis in 762 Proceduresâ€• Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	5
190	Prognosticating Survival in Hepatocellular Carcinoma with Elevated Baseline Alpha-fetoprotein Treated with Radioembolization Using a Novel Laboratory Scoring System: Initial Development and Validation. CardioVascular and Interventional Radiology, 2019, 42, 700-711.	0.9	5
191	Excimer Laser Sheathâ€“Assisted Retrieval of â€œClosedâ€Cellâ€•Design Inferior Vena Cava Filters. Journal of the American Heart Association, 2020, 9, e017240.	1.6	5
192	Feasibility of Combination Intra-arterial Yttrium-90 and Irinotecan Microspheres in the VX2 Rabbit Model. CardioVascular and Interventional Radiology, 2020, 43, 1528-1537.	0.9	5
193	Impact of COVID-19 on IR Fellowship. Journal of Vascular and Interventional Radiology, 2020, 31, 1492-1494.	0.2	5
194	Radioembolisation with personalised dosimetry: improving outcomes for patients with advanced hepatocellular carcinoma. The Lancet Gastroenterology and Hepatology, 2021, 6, 2-3.	3.7	5
195	Fourâ€dimensional transcatheter intraâ€arterial perfusion MR imaging before and after uterine artery embolization in the rabbit VX2 tumor model. Journal of Magnetic Resonance Imaging, 2010, 31, 1137-1143.	1.9	4
196	Types of Research Bias Encountered in IR. Journal of Vascular and Interventional Radiology, 2016, 27, 546-550.	0.2	4
197	Fluoroscopic Radiation Exposure in Chemoembolization and Radioembolization: Results from a Prospective Randomized Study. Journal of Vascular and Interventional Radiology, 2017, 28, 1272-1273.	0.2	4
198	Absorbed dose kernel and selfâ€shielding calculations for a novel radiopaque glass microsphere for transarterial radioembolization. Medical Physics, 2018, 45, 934-942.	1.6	4

#	Article	IF	Citations
199	Clinical Case Panel: Treatment Alternatives for Inoperable Hepatocellular Carcinoma. Seminars in Radiation Oncology, 2018, 28, 295-308.	1.0	4
200	Hepatorenal Syndrome: Physiology, Diagnosis and Management. Seminars in Interventional Radiology, 2018, 35, 194-197.	0.3	4
201	Use of yttrium-90 (Y90) glass microspheres (TheraSphere) as neoadjuvant to transplantation/resection in hepatocellular carcinoma: Analyses from the LEGACY study.. Journal of Clinical Oncology, 2021, 39, 300-300.	0.8	4
202	Functional magnetic resonance imaging in an animal model of pancreatic cancer. World Journal of Gastroenterology, 2010, 16, 3292.	1.4	4
203	Transarterial Yttrium-90 Radioembolization of Hepatocellular Carcinoma Perfused by the Cystic Artery: Multi-institutional Feasibility Study. Journal of Vascular and Interventional Radiology, 2020, 31, 2022-2027.	0.2	4
204	MR Imaging Enables Measurement of Therapeutic Nanoparticle Uptake in Rat N1-S1 Liver Tumors after Nanoablation. Journal of Vascular and Interventional Radiology, 2014, 25, 1288-1294.	0.2	3
205	The law of unintended consequences: current design challenges in inferior vena cava filters. Expert Review of Medical Devices, 2017, 14, 805-810.	1.4	3
206	Contemporary Algorithm for the Management of Hepatocellular Carcinoma in 2021: The Northwestern Approach. Seminars in Interventional Radiology, 2021, 38, 432-437.	0.3	3
207	Radiation Lobectomy: An Overview of Concept and Applications, Technical Considerations, Outcomes. Seminars in Interventional Radiology, 2021, 38, 419-424.	0.3	3
208	The Role of Potentially Retrievable Inferior Vena Cava Filters in High-Risk Patients Undergoing Joint Arthroplasty. Journal of Clinical and Diagnostic Research JCDR, 2015, 9, TC01-3.	0.8	3
209	Optimizing the Use of Inferior Vena Cava Filters in Oncology Patients: Are All Filters Created Equally?. Seminars in Thrombosis and Hemostasis, 2014, 40, 401-406.	1.5	2
210	Rationale of transcatheter intra-arterial therapies of hepatic cancers. Hepatic Oncology, 2014, 1, 285-291.	4.2	2
211	Reinforcing the Importance and Feasibility of Implementing a Low-dose Protocol for CT-guided Biopsies. Academic Radiology, 2018, 25, 1146-1151.	1.3	2
212	Endovascular Management of Acquired Hepatic Arterialâ€“Portal Venous Malformations. CardioVascular and Interventional Radiology, 2020, 43, 466-477.	0.9	2
213	Contemporary Techniques and Applications of Radioembolization in Patients with Hepatocellular Carcinoma. Advances in Clinical Radiology, 2020, 2, 113-125.	0.1	2
214	Yttrium-90 Portal Vein Radioembolization in Sprague–Dawley Rats: Dose-Dependent Imaging and Pathological Changes in Normal Liver. CardioVascular and Interventional Radiology, 2020, 43, 1925-1935.	0.9	2
215	Safety and Outcomes of Permanent and Retrievable Inferior Vena Cava Filters in the Oncology Population. International Journal of Vascular Medicine, 2020, 2020, 1-7.	0.4	2
216	Correlation and Agreement of Yttrium-90 Positron Emission Tomography/Computed Tomography with ExÂVivo Radioembolization Microsphere Deposition in the Rabbit VX2 Liver Tumor Model. Journal of Vascular and Interventional Radiology, 2021, 32, 23-32.e1.	0.2	2

#	Article	IF	Citations
217	Duramycin radiosensitization of MCA-RH 7777 hepatoma cells through the elevation of reactive oxygen species. Journal of Cancer Research and Therapeutics, 2021, 17, 543.	0.3	2
218	Extraordinary Cases in Inferior Vena Cava Filter Retrieval. Seminars in Interventional Radiology, 2016, 33, 149-156.	0.3	1
219	Commentary on: â€œOccupational radiation exposure of medical staff performing 90Y-loaded microsphere radioembolizationâ€. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 822-823.	3.3	1
220	Reply. Gastroenterology, 2017, 152, 1628-1629.	0.6	1
221	Perceptions of Quality in Interventional Oncology. Journal of Vascular and Interventional Radiology, 2018, 29, 367-372.e1.	0.2	1
222	Transarterial Radioembolization (TARE). , 2018, , 389-396.		1
223	CBCT-guided TACE-MWA for HCC Measuring up to 5 cm. Academic Radiology, 2021, 28, S71-S72.	1.3	1
224	Practice gaps and challenges integrating new immuno-oncology agents in the treatment of cancer patients in the United States: A mixed-method study.. Journal of Clinical Oncology, 2020, 38, 11028-11028.	0.8	1
225	Computational Modeling of Radioembolization: How to Calculate Infinity. CardioVascular and Interventional Radiology, 2021, 44, 2020-2021.	0.9	1
226	Embolic Therapies. , 2013, , 101-113.		0
227	Imaging and Image-guided Intervention Are Irrevocably Linked. Radiologic Clinics of North America, 2015, 53, xi.	0.9	0
228	Reply. Hepatology, 2016, 64, 1375-1376.	3.6	0
229	Update on Portal Hypertension. Seminars in Interventional Radiology, 2018, 35, 151-152.	0.3	0
230	Does significantly elevated lung shunt fraction (LSF >20%) promote extrahepatic progression in patients with hepatocellular carcinoma treated with radioembolization?. Nuclear Medicine Communications, 2021, 42, 725-731.	0.5	0
231	Temporary Vena Cava Filters in Oncology Patients. Blood, 2014, 124, 4247-4247.	0.6	0
232	Permanent inferior vena cava filters in patients with active malignancy.. Journal of Clinical Oncology, 2015, 33, e17655-e17655.	0.8	0
233	Temporary and Permanent Inferior Vena Cava Filters in the Oncology Population. Blood, 2016, 128, 1423-1423.	0.6	0
234	Role of Y90 Radioembolization in Hepatic Metastatic Colorectal Carcinoma. , 2020, , 519-529.		0

#	Article	IF	Citations
235	Yttrium-90 Radioembolization in the VX2 Rabbit Model: Radiation Safety and Factors Influencing Delivery Efficiency. Journal of Vascular and Interventional Radiology, 2021, 32, 1569-1574.e11.	0.2	0
236	Complex Filter Retrieval Planning. , 2020, , 39-53.		0